Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China 400016.
Biomed Res Int. 2021 May 1;2021:5541613. doi: 10.1155/2021/5541613. eCollection 2021.
The purpose of the current meta-analysis was to evaluate whether multidisciplinary team improved overall survival of colorectal cancer.
PubMed, EMBASE, and Cochrane Library database were searched from inception to October 25, 2020. The hazard ratio (HR) and 95% confidence (CI) of overall survival (OS) were calculated.
A total of 11 studies with 30814 patients were included in this meta-analysis. After pooling the HRs, the MDT group was associated with better OS compared with the non-MDT group (HR = 0.81, 95% CI 0.69-0.94, = 0.005). In subgroup analysis of stage IV colorectal cancer, the MDT group was associated with better OS as well (HR = 0.73, 95% CI 0.59-0.90, = 0.004). However, in terms of postoperative mortality, no significant difference was found between MDT and non-MDT groups (OR = 0.84, 95% CI 0.44-1.61, = 0.60).
MDT could improve OS of colorectal cancer patients.
本荟萃分析旨在评估多学科团队是否能提高结直肠癌患者的总生存率。
从建库至 2020 年 10 月 25 日，我们检索了 PubMed、EMBASE 和 Cochrane Library 数据库。计算了总生存（OS）的风险比（HR）和 95%置信区间（CI）。
本荟萃分析共纳入 11 项研究，共 30814 例患者。合并 HR 后，MDT 组的 OS 优于非 MDT 组（HR=0.81，95%CI0.69-0.94， = 0.005）。在 IV 期结直肠癌的亚组分析中，MDT 组的 OS 也更好（HR=0.73，95%CI0.59-0.90， = 0.004）。然而，在术后死亡率方面，MDT 组与非 MDT 组之间无显著差异（OR=0.84，95%CI0.44-1.61， = 0.60）。
MDT 可提高结直肠癌患者的 OS。
Zotero 插件
